Development Center for Biotechnology
8 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 5 name spellings.
15
Ending by 2030
Nov 2026
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Apr 6, 2027The maintenance fee for GLP-1 potentiators from hedychium coronarium and their applications (US 9,150,482) comes due Apr 6, 2027. Unpaid by Oct 6, 2027, it lapses early.
- 1 fee due May 26, 2027The maintenance fee for Regioselective one-step process for synthesizing 2-hydroxyquinoxaline (US 10,487,062) comes due May 26, 2027. Unpaid by Nov 26, 2027, it lapses early.
- 1 fee due Aug 18, 2027The maintenance fee for Use of overground part of Hedychium coronarium Koenig in reducing blood glucose; extracts and compositions of overground part of Hedychium coronarium Koenig and their uses (US 10,561,700) comes due Aug 18, 2027. Unpaid by Feb 18, 2028, it lapses early.
- 2 fees due Sep 17 to 29, 2027 · next Sep 17
- 3 fees due Oct 19 to 26, 2027 · next Oct 19
Recent changes
- 1 of the patents on this record was granted since Aug 17, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,247,004 | Plant extracts for treating skin disorders and enhancing healing of wounds for diabetic patients In force · From the USPTO record | In force | From the USPTO record | |
| US 7,531,194 | Plant extracts for the treatment of rheumatoid arthritis In force · From the USPTO record | In force | From the USPTO record | |
| US 8,088,394 | Mutated E. coli heat-labile enterotoxin In force · From the USPTO record | In force | From the USPTO record | |
| US 8,110,197 | Mutated E. coli heat-labile enterotoxin In force · From the USPTO record | In force | From the USPTO record | |
| US 7,824,714 | Chinese herb extract for treating dementia and preparation method thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 8,431,118 | Anti-Herpes Simplex Virus Antibodies and Methods of Use Thereof In force · Medium confidence | In force | Medium confidence | |
| US 7,897,602 | Indolinone compounds as kinase inhibitors In force · From the USPTO record | In force | From the USPTO record | |
| US 8,252,906 | Anti-Herpes Simplex Virus Antibodies and Methods of Use Thereof In force · Medium confidence | In force | Medium confidence | |
| US 7,985,431 | Plant extracts for treating skin disorders and enhancing healing of wounds for diabetic patients In force · From the USPTO record | In force | From the USPTO record | |
| US 9,872,879 | Process for the preparation of plant extracts for treating skin disorders and enhancing healing of wounds In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 47: 8 patents in force now held by others · 9 lapsed for an unpaid fee · 37 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
5 pending · 6 abandoned · 25 no status recorded